Shares of ProMetic Life Sciences Inc. (TSE:PLI) reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as C$0.65 and last traded at C$0.65, with a volume of 1198080 shares traded. The stock had previously closed at C$0.70.
Several analysts recently issued reports on the company. Canaccord Genuity dropped their target price on ProMetic Life Sciences from C$4.00 to C$2.00 in a report on Tuesday, April 3rd. National Bank Financial dropped their target price on ProMetic Life Sciences from C$1.00 to C$0.75 and set an “underperform” rating on the stock in a report on Wednesday, April 4th. TD Securities dropped their target price on ProMetic Life Sciences from C$3.50 to C$2.00 in a report on Monday, April 2nd. CIBC dropped their target price on ProMetic Life Sciences from C$2.15 to C$0.60 in a report on Monday, April 2nd. Finally, Royal Bank of Canada dropped their target price on ProMetic Life Sciences from C$3.50 to C$2.00 and set an “outperform” rating on the stock in a report on Monday, April 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. ProMetic Life Sciences presently has a consensus rating of “Buy” and a consensus price target of C$1.89.
ProMetic Life Sciences (TSE:PLI) last announced its quarterly earnings results on Wednesday, March 28th. The company reported C($0.05) earnings per share for the quarter. The business had revenue of C$6.60 million for the quarter. ProMetic Life Sciences had a negative return on equity of 48.83% and a negative net margin of 73.85%.
In other ProMetic Life Sciences news, Director Dwun-Hou Chen sold 108,566 shares of the business’s stock in a transaction that occurred on Friday, April 6th. The stock was sold at an average price of C$0.86, for a total transaction of C$93,366.76.
About ProMetic Life Sciences
ProMetic Life Sciences Inc, a biopharmaceutical company, develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products. It operates through three segments: Small-Molecule Therapeutics, Plasma-Derived Therapeutics, and Bioseparation Technologies. The company offers its technology platform for purification of biologics, drug development, proteomics, and elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, inflammation, autoimmune diseases, oncology, and nephropathies.
Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.